Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2023 08:00 ET | Source: Incannex Healthcare

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
January 19, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
November 05, 2020 08:04 ET | Source: Arch Biopartners

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...
July 28, 2020 08:13 ET | Source: Arch Biopartners

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
June 08, 2020 07:00 ET | Source: Arch Biopartners

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
May 08, 2020 06:00 ET | Source: Arch Biopartners

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
March 17, 2020 11:21 ET | Source: Arch Biopartners

ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL

TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final...
March 04, 2020 09:56 ET | Source: Arch Biopartners

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...
May 23, 2017 15:30 ET | Source: Qu Biologics

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the...